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 1 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No. Recommendation 
Page  
No. 
Relevant text from 
manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1 Title 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found 
3 Abstract 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 5-6 Covered in introduction 
Objectives 3 State specific objectives, including any prespecified hypotheses 6 Final paragraph of introduction 
Methods  
Study design 4 Present key elements of study design early in the paper 6-10 Described in final paragraph of 
introduction and in-depth in the 
methods section 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, 
follow-up, and data collection 
6-10 Methods 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants 
 This was a retrospective study, 
using large datasets and 
therefore patients were not 
directly recruited 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per 
case 
 NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. 
Give diagnostic criteria, if applicable 
6-10 Methods 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group 
6-10 Methods 
Bias 9 Describe any efforts to address potential sources of bias 12-15 Discussion 
 2 
Study size 10 Explain how the study size was arrived at NA Retrospective study 
Continued on next page   
 3 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
 6-10, methods 
 12 (a) Describe all statistical methods, including those used to control for confounding  6-10, methods 
(b) Describe any methods used to examine subgroups and interactions  6-10, methods 
(c) Explain how missing data were addressed  15, discussion 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
 6-10, methods 
(e) Describe any sensitivity analyses  NA 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
 10 results 
(b) Give reasons for non-participation at each stage  N/A –retrospective study 
(c) Consider use of a flow diagram  N/A – not appropriate 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
 N/A – patient data from huge 
datasets anonymised 
(b) Indicate number of participants with missing data for each variable of interest  N/A – ecological study 
(c) Cohort study—Summarise follow-up time (eg, average and total amount)  N/A 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time  N/A 
Case-control study—Report numbers in each exposure category, or summary measures of exposure  10 Results 
Cross-sectional study—Report numbers of outcome events or summary measures   
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were 
included 
 10-12 Results 
(b) Report category boundaries when continuous variables were categorized  N/A 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
 N/A 
Continued on next page   
 4 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  N/A – 1 analysis done 
Discussion 
Key results 18 Summarise key results with reference to study objectives  10-12 - Results 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
 15 – limitations 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
 12-15 Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results  12-15 Discussion 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
 Given in submission document 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
